P2-080: Amyloid status and neuropsychological profiles in early-onset, late-onset and very late-onset dementia due to probable Alzheimer's disease

including Ab1-42, T-tau and P-tau, Ab1-42/P-tau ratio and AD profile were not different between MCI and DAT subgroups. Based on CSF biomarkers, 25% (n1⁄47) MCI patients showed biomarkers of neurodegeneration without positive markers of amyloid accumulation. Conclusions: After one year of recruitment efforts, this is the first Arg-ADNI report. Arg-ADNI is a growing sample with ongoing recruitment of MCI and AD patients and controls. Follow-up of this important sample, particularly related to CSF and brain biomarkers, will allow better characterization of AD in Argentina, and perhaps point to unique environmental factors influencing brain health in South America. For example, clinical and biochemical follow up of MCI patients with neurodegenerative profiles and without amyloid accumulation may provide important insights.